One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, according to a new study published November 5, 2025, in npj Precision Oncology ...

One person’s side effect could be another person’s treatment if we expand our perspective on small molecule drug targets, ...

Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...

Glioblastoma remains one of the most stubbornly difficult forms of cancer to treat. It is the most common and most aggressive malignant brain tumour, and only half of people survive 12 months after ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...

Genetic modifications in reproductive cells, such as eggs, sperm, or embryos, are commonly referred to as germline editing and are heritable. 1 CRISPR-Cas 9, which stands for clustered regularly ...